



Allergologia et immunopathologia

Sociedad Española de Inmunología Clínica,
Alergología y Asma Pediátrica

www.elsevier.es/ai



ORIGINAL ARTICLE

Interleukin-23 receptor gene polymorphisms in Iranian patients with juvenile systemic lupus erythematosus



A. Rezaei^a, S. Harsini^{a,b}, M. Sadr^c, V. Ziaee^d, N. Rezaei^{a,b,e,*}

^a Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran

^b Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

^c Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran

^d Division of Pediatric Rheumatology, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran

^e Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Received 24 February 2019; accepted 22 May 2019

Available online 30 August 2019

KEYWORDS

Interleukin-23 receptor;
Single nucleotide polymorphism;
Systemic lupus erythematosus;
Children

Abstract

Introduction and objectives: Considering the possible roles of interleukin-23 receptor (IL-23R) gene in the pathogenesis of juvenile systemic lupus erythematosus (JSLE), the objective of this study was to elucidate whether polymorphisms of the *IL23R* are associated with susceptibility to JSLE in an Iranian population.

Materials and methods: A case-control study on 62 patients with JSLE and 78 healthy controls was performed to investigate the associations of four single nucleotide polymorphisms (SNPs) in *IL-23R* gene, namely, rs7517847, rs10489629, rs11209026, and rs1343151, with susceptibility to JSLE, using real-time polymerase chain reaction Taqman genotyping technique.

Results: Analysis of allele and genotype frequency of four selected SNPs revealed statistically significant positive association between homozygous variant of rs7517847 (TT) (P, 0.02) and T allele at the same position (P, 0.01) with JSLE vulnerability. There was no significant association between other evaluated SNPs and JSLE susceptibility.

Conclusion: These findings suggest that particular *IL-23R* gene variants could affect individual susceptibility to JSLE.

© 2019 SEICAP. Published by Elsevier España, S.L.U. All rights reserved.

Introduction

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disorder with diverse clinical manifestations and

* Corresponding author.

E-mail address: rezaei_nima@tums.ac.ir (N. Rezaei).

<https://doi.org/10.1016/j.aller.2019.05.007>

0301-0546/© 2019 SEICAP. Published by Elsevier España, S.L.U. All rights reserved.

unclear pathogenesis. The disease is associated with the production of autoantibodies against nuclear and cytoplasmic components, abnormalities of immune-inflammatory system functions and inflammatory manifestations in several organs.¹ Juvenile systemic lupus erythematosus (JSLE), constitutes 10–20% of all SLE cases and predominantly appears before the age of 16 years.^{2,3} Although JSLE and adult-onset SLE share several features, JSLE is found to be more severe than the adult-onset SLE, leading to higher incidence of organ involvement and more rapid clinical progression.⁴ A complex interplay between genetic risk factors and environmental events is hypothesized to contribute towards disease initiation and progression.^{3,5} Genome-wide association studies have revealed familial tendency for disease expression, such as the evident higher concordance of SLE in monozygotic twins in comparison to healthy subjects.^{1,6} The results of such studies together with the data provided by our previous studies have supported the notion that genetic factors such as the genes coding for cytokines and their receptors could play crucial roles in the pathogenesis of inflammatory disorders such as JSLE.^{7–18}

Interleukin-23 (IL-23) is a heterodimeric cytokine composed of a unique p19 subunit and a common p40 subunit shared with IL-12.¹⁹ IL-23 is mainly expressed through activation of phagocytes and dendritic cells^{20,21} and has been shown to play an essential role in the activation of a subset of CD4+T cells characterized by the production of the interleukin-17 (IL-17), namely, Th17 cells.^{22,23} IL-17 induces the synthesis of proinflammatory cytokines which ultimately leads to chronic inflammation and the destruction of joints.^{21,24} All these findings suggest IL-23 pathway as an important actor in the pathogenesis of chronic inflammatory diseases such as SLE.²² IL-23 exerts its effects through binding to the IL-23 receptor (IL-23R) complex with high affinity.²⁰ IL-23R constitutes a common IL-23 receptor and an IL-12 receptor β 1 subunit, which are mostly expressed on activated and memory T cells.^{22,25} The *IL-23R* gene is positioned on chromosome 1p31, spanning 2.8 kb and comprising 11 exons and 10 introns. The promoter region of the human *IL-23R* gene is distributed with many single nucleotide polymorphisms.²⁶ A multitude of studies have depicted a strong association between *IL-23R* polymorphisms and the progression and outcome of several autoimmune disorders, such as ankylosing spondylitis, Crohn's disease, and rheumatoid arthritis.²¹ The aim of this study was to investigate the role of *IL23R* variants in JSLE susceptibility. Herein, we have examined the association between four selected *IL-23R* polymorphisms and JSLE proneness in Iranian population.

Materials and methods

The study population included 62 consecutive Iranian patients with JSLE (with a mean age of 11 years and range of 4–14 years), who were referred to the Rheumatology Clinic of the Children's Medical Center Hospital, the pediatric center of excellence in Iran, between March 2015 and April 2018, and fulfilled the American College of Rheumatology (ACR) classification criteria for SLE.⁴ Thorough history taking, comprehensive examination and relevant laboratory and radiological studies were carried out for all patients.

Table 1 Details of IL-23R gene single nucleotide polymorphisms (SNPs), gene polymorphisms, positions and locations, assessed in the present investigation.

Gene location	Position	Polymorphism	SNP
Intron	67681669	G/T	rs7517847
Intron	67688349	C/T	rs10489629
Exon	67705958	A/G	rs11209026
Intron	67719129	A/G	rs1343151

Patients diagnosed with any other concomitant disorder were excluded from the study. Seventy-eight ethnically, age and sex matched healthy controls with no family history or clinical manifestation of any rheumatologic and autoimmune disorders were also randomly recruited from those who visited for routine check-ups at the same center. All the patients and controls were unrelated individuals. Written informed consent was obtained from all the subjects' parents or guardians according to the guidelines of the Ethics Committee of Tehran University of Medical Sciences before blood sampling.

Genomic DNA samples were obtained from all the participants and were stored at -20°C until administration. DNA samples of patients and healthy controls were extracted from peripheral blood leukocytes using the phenol-chloroform method. Genotyping of the samples was conducted by real-time polymerase chain reaction (RT-PCR), using TaqMan probe (ABI, USA) with an ABI 7300 RT-PCR instrument (Applied Biosystems). Optical 96-well reaction plate 0.2 μl (ABI, USA) was administered for the test. The total volume of 20 μl in each microwell, consisted of 10 μl Master Mix (ABI, USA), 0.5 μl Assay Mix (ABI, USA), 4.5 μl deionized water, and 5 μl DNA samples with a concentration of 20 ng/ml. PCR conditions were as follows: 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The results were determined using Allelic Discrimination Program (Applied Biosystems).

Genotype and allelic frequencies of certain *IL-23R* SNPs, including rs10489629, rs11209026, rs1343151, and rs7517847 (Table 1) were compared between JSLE cases and controls using the chi-square test and Fisher's exact test when appropriate, and odds ratio (OR) and 95% confidence interval (CI) were calculated to assess the relative risk conferred by a particular allele and genotype. Hardy-Weinberg equilibrium evaluation was performed for each polymorphism included in this research. All SNPs were found to be in Hardy-Weinberg equilibrium (HWE) ($P > 0.05$) in the control group. Statistical significance was assumed at the $p < 0.05$ level. The statistical program Epi Info 7 was used for all statistical analyses.

Results

Allelic and genotype frequencies of rs7517847, rs10489629, rs11209026, and rs1343151 polymorphisms in patients with juvenile systemic lupus erythematosus and healthy control subjects are depicted in Table 2.

Analysis of allele and genotype frequency of four selected SNPs revealed a statistically significant positive association between the homozygous variant of rs7517847 (TT) (76.7%

Table 2 Allele and genotype distribution of *IL-23R* gene in JSLE patients and healthy controls.

SNP	Alleles/genotypes	JSLE (n=62) N (%)	Control (n=78) N (%)	P	OR (95% CI)
<i>IL-23R</i> Rs7517847 ^a	T	106 (88.3)	118 (75.6)	0.01	2.43 (1.25-4.74)
	G	14 (11.7)	38 (24.4)	0.01	0.41 (0.21-0.79)
	TT	46 (76.7)	44 (56.4)	0.02	2.53 (1.20-5.35)
	TG	14 (23.3)	30 (38.5)	0.08	0.48 (0.22-1.03)
	GG	0 (0)	4 (5.13)	0.20	-
<i>IL-23R</i> Rs10489629	T	93 (75)	106 (67.9)	0.24	1.41 (0.83-2.39)
	C	31 (25)	50 (32.1)	0.24	0.70 (0.41-1.19)
	TT	34 (54.8)	37 (47.4)	0.43	1.34 (0.68-2.62)
	TC	25 (40.3)	32 (41)	1.00	0.97 (0.49-1.91)
	CC	3 (4.8)	9 (11.5)	0.27	0.38 (0.10-1.05)
<i>IL-23R</i> Rs11209026	G	118 (95.2)	150 (96.2)	0.9	0.78 (0.24-2.50)
	A	6 (4.8)	6 (3.9)	0.9	1.27 (0.39-4.04)
	GG	57 (91.9)	72 (92.3)	1.00	0.95 (0.27-3.27)
	GA	4 (6.5)	6 (7.7)	1.00	0.82 (0.22-3.0)
	AA	1 (1.6)	0 (0)	0.90	-
<i>IL-23R</i> Rs1343151	G	102 (82.3)	106 (67.95)	0.09	1.70 (0.95-3.05)
	A	22(17.7)	50 (32)	0.09	0.58 (0.32-1.04)
	GG	42(67.7)	41 (52.6)	0.1	1.89 (0.94-3.79)
	GA	18(29)	32 (41)	0.19	0.58 (0.28-1.19)
	AA	2(3.2)	5 (6.4)	0.63	0.48 (0.09-2.59)

JSLE: Juvenile systemic lupus erythematosus; OR: odds ratio; CI: confidence interval.

^a Number of patients was 60 in this group.

vs. 56.4%; P, 0.02; OR, 2.53; 95%CI, 1.20–5.35) and T allele at the same position (88.3% vs. 75.6%; P, 0.01; OR, 2.43; 95%CI, 1.25–4.74) with JSLE vulnerability in our study. There was no significant association between other evaluated SNPs and JSLE susceptibility.

Discussion

To the best of our knowledge, the present investigation is the first to assess the correlation between *IL-23R* polymorphisms, which have been previously postulated as a possible genetic marker for autoimmunity,²² and JSLE in an Iranian population. Our results showed statistically significant correlation between both the *IL-23R* rs7517847 T allele and TT genotype and individuals' susceptibility to JSLE. On the other hand, we could not detect any significant difference between the case and control groups in the frequency of *IL-23R* rs11209026, rs1343151, and rs10489629 variants.

The results of the current investigation are not in line with the findings of the study conducted by Yi Li et al. demonstrating no significant differences in the genotype and allele frequencies of rs10889677, rs1884444, and rs7517847 polymorphisms between the patients with SLE and the control group in a Chinese population.²⁷ In another study, Sanchez et al. evaluated eight *IL-23R* SNPs (rs1004819, rs7517847, rs10489629, rs11209026, rs1343151, rs10889677, rs11209032, and rs1495965) and revealed no statistically significant differences between SLE patients and healthy controls of Spanish origin.²² The results of these above-mentioned investigations are consistent with the findings of a study conducted by Kim et al. showing lack of association between seven *IL-23R* SNPs (rs1004819, rs7517847, rs10489629, rs2201841, rs1343151, rs11209032,

and rs1495965) and SLE susceptibility in a sample of over 600 Korean SLE patients and almost 1000 healthy controls.²⁸ Consistently, Safrany et al. observed no significant difference in the *IL-23R* rs11805303, rs10889677, rs1004819, rs2201841, rs11209032, rs11209026, rs10489629, rs7517847, and rs7530511 variants between the SLE patient and control groups in the Hungarian population.²⁹ In 2018, Imani et al.²¹ performed a systematic review and meta-analysis, pooling the results of all the four above-said studies, and depicted a significant association between the *IL-23R* gene rs7517847 T>G SNP and SLE risk, in line with our results. Our literature search also revealed another study,³⁰ assessing *IL-23R* rs10889677, and rs1884444 SNPs, indicating lack of association of these polymorphisms with SLE susceptibility or severity. Notwithstanding the fact that our investigation implied rs7517847 variant of *IL23R* as a novel susceptibility gene in JSLE, the lack of association between certain *IL-23R* gene variants and SLE vulnerability found in a number of previous studies could possibly indicate that *IL-23R* may play an important role in regulating local inflammation rather than systemic inflammatory processes involved in systemic autoimmune disease such as systemic sclerosis.^{31,32} However, *IL-23R* gene was found to be associated with organ-characteristic autoimmune diseases such as inflammatory bowel disease,³³ experimental autoimmune encephalomyelitis,³⁴ rheumatoid arthritis,³⁵ ankylosing spondylitis³⁶ and psoriasis.³⁷ This lack of association could also be partly attributed to the fact that *IL-23* preferentially stimulates T cells to produce cytokines, including tumor necrosis factor- α , IL-6, and IL-17, but does not provoke the production of type I interferons, which are assumed to play a relevant role in the development and maintenance of the disease process in SLE.^{38,39}

It should be noted that the current study has some certain constraints, including the relatively small number of participants in the patients' category, resulting in diminished statistical power of the analysis; together with our limitation to measure serum levels of IL-23 and IL-17, which altogether limits the ability of our investigation to reach a consolidated answer to the questions considering the precise role of the above-mentioned gene variants in both the cytokines' production and JSLE pathogenesis.

To conclude, the results of the current investigation suggested rs7517847 variant of *IL23R* as a novel susceptibility gene in JSLE. However, as this gene is not yet widely evaluated in JSLE patients, we are unable to incisively accept or reject the definite role of this gene in the pathogenesis of JSLE. Further multi-center studies enrolling larger sample sizes of different ethnicities are required to confirm this finding.

Funding

This study was supported by a grant from Tehran University of Medical Sciences (95-03-154-32285).

Conflict of interest

It should be noted that there is no ethical problem (approved by the research ethics committee of Tehran University of Medical Sciences) or conflict of interest in our research. There was no honorarium, grant, or other form of payment to authors to produce the manuscript.

References

- Mireles-Canales MP, González-Chávez SA, Quiñonez-Flores CM, León-López EA, et al. DNA damage and deficiencies in the mechanisms of its repair: implications in the pathogenesis of systemic lupus erythematosus. *J Immunol Res*. 2018;2018.
- Jaybhaye AP, Sutay NR, Chate SV, Rathod TN. Juvenile systemic lupus erythematosus: a diagnostic dilemma. *J Nat Sci Biol Med*. 2011;2:229.
- Tahghighi F, Ziaee V, Moradinejad MH, Rezaei A, Harsini S, Soltani S, et al. Tumor necrosis factor-alpha single nucleotide polymorphisms in juvenile systemic lupus erythematosus. *Human Immunol*. 2015;76:533-6.
- Fortuna G, Brennan MT. Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management. *Dent Clin*. 2013;57:631-55.
- Sule S, Rosen A, Petri M, Akhter E, Andrade F. Abnormal production of pro-and anti-inflammatory cytokines by lupus monocytes in response to apoptotic cells. *PLoS One*. 2011;6:e17495.
- Gehrke N, Mertens C, Zillinger T, Wenzel J, Bald T, Zahn S, et al. Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. *Immunity*. 2013;39:482-95.
- Harsini S, Saghadzadeh A, Nedjat S, Rezaei N. Associations between interleukin-10 polymorphisms and susceptibility to juvenile idiopathic arthritis: a systematic review and meta-analysis. *Eur Cytokine Network*. 2018;29:16-26, <http://dx.doi.org/10.1684/ecn.2018.0404>.
- Maddah M, Harsini S, Ziaee V, Moradinejad MH, Rezaei A, Zoghi S, et al. Association of tumour necrosis factor-alpha G/A -238 and G/A -308 single nucleotide polymorphisms with juvenile idiopathic arthritis. *Int J Immunogenet*. 2016;43:391-6, <http://dx.doi.org/10.1111/iji.12291>.
- Ziaee V, Maddah M, Harsini S, Rezaei A, Sadr M, Zoghi S, et al. Association of interleukin-1 family gene polymorphisms with juvenile idiopathic arthritis in Iranian population. *Allergologia et immunopathologia*. 2016;44:542-6, <http://dx.doi.org/10.1016/j.aller.2016.07.002>.
- Ziaee V, Maddah M, Moradinejad MH, Rezaei A, Zoghi S, Sadr M, et al. Association of interleukin-6 single nucleotide polymorphisms with juvenile idiopathic arthritis. *Clin Rheumatol*. 2017;36:77-81, <http://dx.doi.org/10.1007/s10067-016-3407-6>.
- Harsini S, Ziaee V, Tahghighi F, Mahmoudi M, Rezaei A, Soltani S, et al. Association of interleukin-2 and interferon-gamma single nucleotide polymorphisms with Juvenile systemic lupus erythematosus. *Allergologia et immunopathologia*. 2016;44:422-6, <http://dx.doi.org/10.1016/j.aller.2015.12.005>.
- Harsini S, Ziaee V, Maddah M, Rezaei A, Sadr M, Zoghi S, et al. Interleukin 10 and transforming growth factor beta 1 gene polymorphisms in juvenile idiopathic arthritis. *Bratislavské lekárske listy*. 2016;117:258-62.
- Maddah M, Harsini S, Rezaei A, Sadr M, Zoghi S, Moradinejad MH, et al. Association of Interleukin-2, but not Interferon-Gamma, single nucleotide polymorphisms with juvenile idiopathic arthritis. *Allergologia et immunopathologia*. 2016;44:303-6, <http://dx.doi.org/10.1016/j.aller.2015.10.005>.
- Ziaee V, Rezaei A, Harsini S, Maddah M, Zoghi S, Sadr M, et al. Polymorphisms of genes encoding interleukin-4 and its receptor in Iranian patients with juvenile idiopathic arthritis. *Clin Rheumatol*. 2016;35:1943-8, <http://dx.doi.org/10.1007/s10067-016-3224-y>.
- Tahghighi F, Ziaee V, Moradinejad MH, Rezaei A, Harsini S, Soltani S, et al. Tumor necrosis factor-alpha single nucleotide polymorphisms in juvenile systemic lupus erythematosus. *Human Immunol*. 2015;76:533-6, <http://dx.doi.org/10.1016/j.humimm.2015.06.011>.
- Rezaei A, Ziaee V, Sharabian FT, Harsini S, Mahmoudi M, Soltani S, et al. Lack of association between interleukin-10, transforming growth factor-beta gene polymorphisms and juvenile-onset systemic lupus erythematosus. *Clin Rheumatol*. 2015;34:1059-64, <http://dx.doi.org/10.1007/s10067-015-2877-2>.
- Mahmoudi M, Tahghighi F, Ziaee V, Harsini S, Rezaei A, Soltani S, et al. Interleukin-4 single nucleotide polymorphisms in juvenile systemic lupus erythematosus. *Int J Immunogenet*. 2014;41:512-7, <http://dx.doi.org/10.1111/iji.12152>.
- Ziaee V, Tahghighi F, Moradinejad MH, Harsini S, Mahmoudi M, Rezaei A, et al. Interleukin-6, interleukin-1 gene cluster and interleukin-1 receptor polymorphisms in Iranian patients with juvenile systemic lupus erythematosus. *Eur Cytokine Network*. 2014;25:35-40, <http://dx.doi.org/10.1684/ecn.2014.0352>.
- Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. *J Exp Med*. 2005;201:233-40.
- Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. *Immunity*. 2000;13:715-25.
- Imani D, Rezaei R, Poorsheikhani A, Alizadeh S, Mahmoudi M. Association of IL-23R gene rs7517847 T>G SNP and susceptibility to systemic lupus erythematosus: a systematic review and meta-analysis. *Rheumatol Res*. 2018;3:13-20.
- Sanchez E, Rueda B, Callejas J, Sabio J, Ortego-Centeno N, Jimenez-Alonso J, et al. Analysis of interleukin-23 receptor (IL23R) gene polymorphisms in systemic lupus erythematosus. *Tissue Antigens*. 2007;70:233-7.

23. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23–IL-17 immune pathway. *Trend Immunol.* 2006;27:17–23.
24. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. *Ann Rev Immunol.* 2009;27:485–517.
25. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. *Immunity.* 2003;19:641–4.
26. Liu Y, Krueger J, Bowcock A. Psoriasis: genetic associations and immune system changes. *Genes Immunity.* 2007;8:1.
27. Li Y, Liang W-B, Li C, Gao L-B, Zhou B, Wang Y-Y, et al. The association between interleukin-23 receptor gene polymorphisms and systemic lupus erythematosus. *DNA Cell Biol.* 2010;29:79–82.
28. Kim H-S, Kim I, Kim JO, Bae JS, Shin HD, Bae S-C. No association between interleukin 23 receptor gene polymorphisms and systemic lupus erythematosus. *Rheumatol Int.* 2009;30:33–8.
29. Safrany E, Hobor R, Jakab L, Tarr T, Csongei V, Jaromi L, et al. Interleukin-23 receptor gene variants in Hungarian systemic lupus erythematosus patients. *Inflamm Res.* 2010;59:159–64.
30. Chen GM, Feng CC, Ye QL, Wang J, Cen H, Li R, et al. Lack of association between IL-23R gene polymorphisms and systemic lupus erythematosus in a Chinese population. *Inflamm Res.* 2013;62:791–5, <http://dx.doi.org/10.1007/s00011-013-0636-x>.
31. Rueda B, Broen J, Torres O, Simeon C, Ortego-Centeno N, Schrijvenaars MM, et al. The interleukin 23 receptor gene does not confer risk to systemic sclerosis and is not associated with systemic sclerosis disease phenotype. *Ann Rheumat Dis.* 2009;68:253–6, <http://dx.doi.org/10.1136/ard.2008.096719>.
32. Farago B, Magyari L, Safrany E, Csongei V, Jaromi L, Horvathovich K, et al. Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis. *Ann Rheumat Dis.* 2008;67:248–50, <http://dx.doi.org/10.1136/ard.2007.072819>.
33. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science (NY).* 2006;314:1461–3, <http://dx.doi.org/10.1126/science.1135245>.
34. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. *Nature.* 2003;421:744–8, <http://dx.doi.org/10.1038/nature01355>.
35. Zhai Y, Xu K, Huang F, Peng H, Feng CC, Zhu KK, et al. Association of interleukin 23 receptor gene polymorphisms (rs10489629, rs7517847) with rheumatoid arthritis in European population: a meta-analysis. *Mol Biol Rep.* 2012;39:8987–94, <http://dx.doi.org/10.1007/s11033-012-1768-8>.
36. Karaderi T, Harvey D, Farrar C, Appleton LH, Stone MA, Sturrock RD, et al. Association between the interleukin 23 receptor and ankylosing spondylitis is confirmed by a new UK case-control study and meta-analysis of published series. *Rheumatology (Oxford, England).* 2009;48:386–9, <http://dx.doi.org/10.1093/rheumatology/ken501>.
37. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. *Am J Human Genet.* 2007;80:273–90, <http://dx.doi.org/10.1086/511051>.
38. Sanchez E, Morales S, Paco L, Lopez-Nevot MA, Hidalgo C, Jimenez-Alonso J, et al. Interleukin 12 (IL12B), interleukin 12 receptor (IL12RB1) and interleukin 23 (IL23A) gene polymorphism in systemic lupus erythematosus. *Rheumatology (Oxford, England).* 2005;44:1136–9, <http://dx.doi.org/10.1093/rheumatology/keh697>.
39. Ronnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. *Arthritis Rheumatism.* 2006;54:408–20, <http://dx.doi.org/10.1002/art.21571>.